Quality management systems (QMS) for biologics

Electronic quality management systems (eQMS) that digitize document control, deviation/CAPA, training records and audit management for biologics and biopharma manufacturers into one 21 CFR Part 11-compliant record, with an AI-assisted compliance layer now reshaping how fast that record can be built and audited.

verified 18 Aug 2026 valid until confidence HIGH 30 sources
fda ema

01Overview and value chain#

Markers EC: Digitized, audit-ready quality-record management for biologics manufacturing | OECD: Biopharmaceutical manufacturing & quality | Regulator: FDA (US), EMA (EU)

An electronic quality management system (eQMS) replaces the paper- and spreadsheet-based document control, deviation, CAPA, training and audit-management processes a biologics manufacturer must run to stay in continuous compliance. Veeva Vault QMS is part of Veeva’s broader Vault platform for biopharma, connecting quality records to the same cloud data model used across the company’s regulatory and clinical products. MasterControl, describing itself as a leading provider of a validated eQMS for life sciences, launched an AI-powered SOP Analyzer in January 2026 that checks standard operating procedures against regulatory requirements, cutting update time from days to hours. ETQ, part of Hexagon’s ALI division, unveiled Reliance AI in January 2026, describing it as an “always intelligent” quality-management ecosystem with native AI features for form-field guidance and complaint/feedback handling. Intelex markets its platform directly to pharmaceutical manufacturers for GMP process improvement. AssurX provides configurable enterprise quality and regulatory-compliance software specifically for pharmaceutical, biotech and medical-device organizations, including FDA QMSR-transition and inspection-readiness support aligned to ISO 13485. Qualio, positioning itself as a life-sciences GRC platform, launched Compliance Intelligence in 2025 — an AI-powered gap-analysis tool that the company says cuts audit preparation from months to days.

The key directions of QMS for biologics are:

  1. Document control and change management: digitizing SOPs, work instructions and controlled documents with version history, approval routing and change-control workflows.
  2. Deviation and CAPA management: capturing quality events, driving root-cause investigation, and tracking corrective and preventive actions to closure with a full audit trail.
  3. Training-record management: linking each controlled document to the specific personnel required to be trained on it, and tracking training completion as a gating condition for task execution.
  4. AI-assisted compliance analysis: a 2026 wave of AI features across the category — SOP analysis against regulatory text, automated gap analysis, and always-on compliance monitoring — compressing tasks that used to take weeks into hours.

Sectoral value chain#

[Document control & change management] ──> [Deviation capture & investigation] ──> [CAPA tracking to closure]
                                                                    │
                                                        (Training-record linkage)
                                                                    │
                    [Audit-readiness reporting] <──── [AI-assisted compliance analysis] <─── [Continuous compliance monitoring]
Fig. 1— Sectoral value chain

Value chain levels#

LevelDescriptionKey inputs/outputs
Document controlDigitizing SOPs and controlled documents with version history and approval routing.In: Draft SOPs/work instructions.
Out: Version-controlled, approved documents.
Deviation capture & investigationRecording a quality event and driving structured root-cause investigation.In: Reported quality event.
Out: Investigated deviation record.
CAPA tracking to closureAssigning, tracking and closing corrective and preventive actions with a full audit trail.In: Investigated deviation record.
Out: Closed CAPA record.
Training-record linkageLinking each controlled document to required personnel and tracking completion.In: Version-controlled documents, personnel roster.
Out: Training-completion status.
AI-assisted compliance analysisApplying AI to analyze SOPs against regulatory text and flag emerging compliance gaps.In: Controlled documents, regulatory text.
Out: Compliance gap analysis.
Audit-readiness reportingCompiling the full connected quality record into an inspection-ready report.In: All prior-level outputs.
Out: Audit-ready compliance report.
Table 1— Value chain levels

Cross-cutting technologies of the sector:

  • Electronic quality management systems (eQMS): cloud or on-premises software that digitizes document control, deviation/CAPA, training records and audit management into one connected, 21 CFR Part 11-compliant quality record.
  • AI-powered compliance automation: machine-learning features layered on top of an eQMS that draft or analyze SOPs against regulatory requirements, flag emerging compliance gaps, or accelerate audit-readiness gap analysis.

02US#

The United States hosts the deepest concentration of eQMS vendors serving biologics and biopharma manufacturers, several shipping major AI-powered releases in the same January 2026 window.

MasterControl’s SOP Analyzer, ETQ’s Reliance AI, AssurX’s ISO 13485-aligned QMSR support, Intelex’s GMP focus#

  • Veeva Vault QMS: part of Veeva’s broader Vault platform for biopharma, unifying quality records on the same cloud data model used across the company’s regulatory and clinical products.
  • MasterControl: launched an AI-powered SOP Analyzer in January 2026 that checks SOPs against regulatory requirements, cutting update time from days to hours.
  • ETQ: part of Hexagon’s ALI division, unveiled Reliance AI in January 2026 with native AI features for form-field guidance and complaint/feedback handling.
  • Intelex: markets its platform directly to pharmaceutical manufacturers for GMP process improvement across quality outcomes.
  • AssurX: configurable enterprise quality and regulatory-compliance software for pharmaceutical, biotech and medical-device organizations, including FDA QMSR-transition and ISO 13485-aligned inspection-readiness support.

03CN#

China is covered qualitatively rather than by a live-screened Chinese vendor: candidate Chinese eQMS firms searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Chinese biologics manufacturers exporting to regulated markets typically deploy the same global eQMS platforms sold worldwide rather than a confirmed distinct domestic alternative.

No confirmed domestic vendor; global platforms serve export-facing manufacturers#

  • Global platform use: Chinese biologics manufacturers targeting FDA- or EMA-regulated export markets typically deploy the same global eQMS platforms used by Western manufacturers, for direct compatibility with those regulators’ expectations.
  • Domestic gap: no China-headquartered eQMS vendor confirmed by a live 2026 source was found during this screen.

04EU#

No EU-headquartered vendor cleared the confirmation bar on this screen distinct from the US-headquartered platforms already tabled; European biologics manufacturers are served by the same global vendors listed above, several of which maintain dedicated EU operations and EMA-aligned compliance features.

Served by the same global platforms rather than a distinct EU-headquartered specialist#

  • EU deployment of global platforms: the vendors tabled above serve EU biologics manufacturers directly, with EMA-aligned (rather than only FDA-aligned) compliance framing built into their platforms.
  • No distinct EU-headquartered vendor confirmed: this screen did not surface an EU-headquartered eQMS specialist distinct from the platforms already listed.

05Leading companies and research institutes#

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Veeva Vault QMS🇺🇸 USAVault QMSUnified Vault cloud data modelcommercial
MasterControl🇺🇸 USAMasterControl eQMS, SOP AnalyzerAI-powered SOP compliance analysiscommercial
ETQ🇺🇸 USAReliance, Reliance AINative AI form-field & complaint handlingcommercial
Intelex🇨🇦 CanadaIntelex QMSGMP process-improvement focuscommercial
AssurX🇺🇸 USAAssurX QMSFDA QMSR transition, ISO 13485-alignedcommercial
Qualio🇺🇸 USAQualio GRC platform, Compliance IntelligenceAI-powered audit-prep gap analysiscommercial
Table 2— Leading companies and research institutes

06Tech stack and innovations#

The QMS-for-biologics technology stack shifted decisively toward AI-assisted compliance in the January 2026 release window:

  1. Connected quality-record data models:
    • Veeva Vault QMS unifies quality records on the same cloud data model as the company’s regulatory and clinical Vault products, avoiding a separate quality-data silo.
  2. AI-powered SOP and compliance analysis:
    • MasterControl’s SOP Analyzer and Qualio’s Compliance Intelligence both apply AI to cut document-review and audit-preparation time from days or months to hours.
  3. Always-on intelligent quality ecosystems:
    • ETQ’s Reliance AI frames its native AI features as continuously monitoring rather than periodically checked, shifting the category from point-in-time review to ongoing compliance assurance.

07Value chains and production pipelines#

Industrial pipeline for biologics quality-record management#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Document control &       │ ───> │ 2. Deviation capture &      │
│    change management            │      │    investigation                 │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Training-record          │ <─── │ 3. CAPA tracking to         │
│    linkage                      │      │    closure                       │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. AI-assisted compliance   │ ───> │ 6. Audit-readiness          │
│    analysis                     │      │    reporting                     │
└───────────────────────────┘      └───────────────────────────┘
Fig. 2— Industrial pipeline for biologics quality-record management

Stage 1: Document control and change management

SOPs and controlled documents are digitized with version history, approval routing and change-control workflows.

Stage 2: Deviation capture and investigation

A reported quality event is captured and driven through a structured root-cause investigation.

Stage 3: CAPA tracking to closure

Corrective and preventive actions are assigned, tracked and closed with a full audit trail linking back to the originating deviation.

Stage 4: Training-record linkage

Each controlled document is linked to the personnel required to be trained on it, with completion tracked as a gating condition for task execution.

Stage 5: AI-assisted compliance analysis

AI analyzes SOPs and quality records against current regulatory text, flagging emerging compliance gaps before an inspection surfaces them.

Stage 6: Audit-readiness reporting

The full connected quality record is compiled into an inspection-ready report, compressing what used to be a manual, weeks-long preparation into a fast, on-demand output.

SupplierRegion & tags
Veeva Vault QMSUS
MasterControlUS
ETQUS
IntelexNorth America
AssurXUS
QualioUS
AI Recommendation

Key directions:

  1. Document control and change management — digitizing SOPs and controlled documents with version history, approval routing and change-control workflows.
  2. Deviation and CAPA management — capturing quality events, driving root-cause investigation, and tracking corrective/preventive actions to closure.
  3. Training-record management — linking each controlled document to the personnel required to be trained on it and tracking completion.
  4. AI-assisted compliance analysis — a 2026 wave of AI features compressing SOP review and audit-prep tasks from weeks to hours.

Regulatory:

  • 21 CFR Part 11 electronic-record and electronic-signature requirements are the baseline every vendor in this category is built to satisfy, not an optional add-on.
  • FDA’s Quality Management System Regulation (QMSR) transition, aligning device-quality expectations more closely with ISO 13485, is actively reshaping vendor feature roadmaps in 2026.
  • An eQMS’s audit trail is itself evidence regulators examine during an inspection — a gap or inconsistency in the trail is a finding in its own right, independent of the underlying quality event.

Companies not in table: Sparta Systems’ TrackWise Quality Suite (now under Honeywell) is a genuine industry-standard QMS platform, but Honeywell already appears in the “SCADA & MES for bioproduction” article for its separate SCADA/MES role — tabling it again here for a different product risked the same kind of category overlap avoided in the bioprocess-historian screen, so it was left out.

Processing note: no China-headquartered or EU-headquartered vendor cleared the confirmation bar distinct from the US/Canada-headquartered platforms tabled — both sections describe how manufacturers in those regions deploy the same global platforms rather than a confirmed regional alternative.

Category boundary: this is distinct from regulatory submission management (Veeva RIM) and from GMP document management as standalone categories — QMS here is the connected hub covering deviation, CAPA and training records specifically, not the document-repository or submission-filing layers on their own.

Sources

30 sources · 6 organisations · retrieved 18 Aug 2026 · confidence HIGH
  1. Veeva Vault QMS · US
  2. MasterControl QMS · US
  3. ETQ Reliance · US
  4. Intelex QMS · CA
  5. AssurX QMS · US
  6. Qualio QMS · US
Cite this dossier
Bioecon (2026). Quality management systems (QMS) for biologics. Bioecon — independent bioeconomy intelligence platform. verified 18 August 2026. https://en.bioecon.ru/technology/qms-for-biologics/
Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.